Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Coupang Inc (CPNG) vs Crispr Therapeutics AG (CRSP) Price & Performance

Coupang IncTrade
Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

Coupang Inc vs Crispr Therapeutics AG — how do they compare? Coupang Inc trades at $17.69 (market cap $32.17B), while Crispr Therapeutics AG trades at $50.02 (market cap $4.97B). The key difference: Coupang Inc is far larger — about 6.5× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.

CPNGCRSP
Market Cap
$32.17B$4.97B
Sector
Consumer CyclicalHealth
52-Week High
$33.53$76.78
52-Week Low
$15.12$44.34
Enterprise Value
$31.26B$3.32B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Coupang Inc

CPNG trades at $17.92, down 4.68% today, with a bearish technical signal and mixed earnings. Revenue grew to $34.53B in 2025, but net income margin is negative at -0.47%. Recent news includes a $412M fine for a data breach in South Korea (Reuters, 2026-06-11). The stock faces regulatory headwinds but maintains strong analyst support with an 87.5% buy rating and a $25.80 consensus target.

Outlook: CPNG offers growth potential from e-commerce expansion but carries risks from regulatory fines and profitability challenges. Investors should weigh strong cash flow against recent earnings misses and legal issues. The stock's current price is 30% below the consensus target, presenting upside if execution improves.

Crispr Therapeutics AG

CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.

The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.

Returns comparison

Trailing returns across standard periods

About Coupang Inc

Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.

Read more on CPNG

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP